2024-512082-14-00CompletedPhase 2
Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 12 Apr 2024
- Start date
- 6 Dec 2021
- Lead sponsor
- Institut Gustave Roussy
- Diseases
- Triple-negative breast cancer
- EU CT number
- 2024-512082-14-00
- EudraCT number
- 2020-006106-23
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 100
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Bergonie | Bordeaux | France | Completed |
| Centre Jean Perrin | Clermont-Ferrand | France | Completed |
| Centre Leon Berard | Lyon | France | Completed |
| Institut Gustave Roussy | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.